Phase III trial of ciclosporin for the prevention of reperfusion injury after myocardial infarction in China.

Trial Profile

Phase III trial of ciclosporin for the prevention of reperfusion injury after myocardial infarction in China.

Planning
Phase of Trial: Phase III

Latest Information Update: 26 May 2015

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Myocardial infarction; Reperfusion injury
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 May 2015 According to NeuroVive Pharmaceutical media release, data from this trial will be used to seek market approval for CicloMulsion in a number of Asian countries for the treatment of reperfusion injury following myocardial infarct.
    • 04 Jun 2013 New trial record
    • 29 May 2013 An application to conduct this trial is being prepared for the Chinese health care regulation agency, according to a NeuroVive media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top